Citations

Clear

4802 citation(s) found for "Yu, Jennifer".

Effects Of A Chronic Warm-up Exercise Routine For Violinists
Sonnek, Abigail, Lautz, Nina, Dahl, Ann, Holbein, Jennifer

Mayo Clinic

Medicine & Science in Sports & Exercise | July 12, 2021 | Volume: 53 | Issue: 8S | Pages: 452-452

10.1249/01.mss.0000764496.69635.ec Get It

The Paws Project: The Impact Of Social Distancing On Physical Activity During The COVID-19 Pandemic
Isautier, Jennifer , Ziegler, Briana, Morris, Sarah J. , Johnson, Bruce D. , Wheatley, Courtney M. , Cross, Troy J. , Taylor, Bryan J.

Mayo Clinic

Medicine & Science in Sports & Exercise | July 12, 2021 | Volume: 53 | Issue: 8S | Pages: 191-191

10.1249/01.mss.0000761284.70164.d8 Get It

The Paws Project: Changes In Physical Activity And Mental Health During The COVID-19 Pandemic
Isautier, Jennifer , Ziegler, Briana, Morris, Sarah J. , Johnson, Bruce D. , Wheatley, Courtney M. , Cross, Troy J. , Taylor, Bryan J.

Mayo Clinic

Medicine & Science in Sports & Exercise | July 12, 2021 | Volume: 53 | Issue: 8S | Pages: 191-191

10.1249/01.mss.0000761280.27443.1b Get It

Malnutrition, Frailty, and Sarcopenia in Patients With Cirrhosis: 2021 Practice Guidance by the American Association for the Study of Liver Diseases
Lai, Jennifer C. , Bernal, William , Tapper, Elliot B. , Ekong, Udeme D. , Carey, Elizabeth J. , Tapper, Elliot B , Ekong, Udeme , Lai, Jennifer , Tandon, Puneeta , Dasarathy, Srinivasan

Mayo Clinic

Hepatology | July 7, 2021 | Volume: 74 | Issue: 3 | Pages: 1611-1644

10.1002/hep.32049 | PMID 34233031 Get It

Metabolic Enzyme DLST Promotes Tumor Aggression and Reveals a Vulnerability to OXPHOS Inhibition in High-Risk Neuroblastoma
Anderson, Nicole , Qin, Xiaodan , Finan, Jennifer M. , Lam, Andrew , Athoe, Jacob, Missiaen, Rindert , Skuli, Nicolas , Kennedy, Annie, Saini, Amandeep S. , Tao, Ting , Zhu, Shizhen , Nissim, Itzhak , Look, A. Thomas , Qing, Guoliang , Simon, M. Celeste , Feng, Hui , Tao, Ting , Anderson, Nicole M., Kennedy, Annie

Mayo Clinic

Cancer Research | July 7, 2021 | Volume: 81 | Issue: 17 | Pages: 4417-4430

10.1158/0008-5472.can-20-2153 | PMID 34233924 Get It

Abstract High-risk neuroblastoma remains therapeutically challenging to treat, and the mechanisms promoting disease aggression are poorly understood. Here, we show that elevated expression of dihydrolipoamide S-succinyltransferase (DLST) predicts poor treatment outcome and aggressive disease in patients with neuroblastoma. DLST is an E2 component of the α-ketoglutarate (αKG) dehydrogenase complex, which governs the entry of glutamine into the tricarboxylic acid cycle (TCA) for oxidative decarboxylation. During this irreversible step, αKG is converted into succinyl-CoA, producing NADH for oxidative phosphorylation (OXPHOS). Utilizing a zebrafish model of MYCN-driven neuroblastoma, we demonstrate that even modest increases in DLST expression promote tumor aggression, while monoallelic dlst loss impedes disease initiation and progression. DLST depletion in human MYCN-amplified neuroblastoma cells minimally affected glutamine anaplerosis and did not alter TCA cycle metabolites other than αKG. However, DLST loss significantly suppressed NADH production and impaired OXPHOS, leading to growth arrest and apoptosis of neuroblastoma cells. In addition, multiple inhibitors targeting the electron transport chain, including the potent IACS-010759 that is currently in clinical testing for other cancers, efficiently reduced neuroblastoma proliferation in vitro. IACS-010759 also suppressed tumor growth in zebrafish and mouse xenograft models of high-risk neuroblastoma. Together, these results demonstrate that DLST promotes neuroblastoma aggression and unveils OXPHOS as an essential contributor to high-risk neuroblastoma. Significance: These findings demonstrate a novel role for DLST in neuroblastoma aggression and identify the OXPHOS inhibitor IACS-010759 as a potential therapeutic strategy for this deadly disease.
Phase 1 study of safety, tolerability and immunogenicity of the human telomerase (hTERT)-encoded DNA plasmids INO-1400 and INO-1401 with or without IL-12 DNA plasmid INO-9012 in adult patients with solid tumors
Vonderheide, Robert H. , Kraynyak, Kimberly A. , Shields, Anthony F. , McRee, Autumn J. , Johnson, Jennifer M. , Sun, Weijing , Pawlicki, Jan M. , Sylvester, Albert J. , McMullan, Trevor, Samuels, Robert J., Kim, Joseph , Boyer, Jean , Morrow, Matthew P. , Humeau, Laurent, Skolnik, Jeffrey , Kraynyak, Kimberly A , Chintakuntlawar, Ashish V. , Samuels, Robert, Weiner, David B

Mayo Clinic

Journal for ImmunoTherapy of Cancer | July 6, 2021 | Volume: 9 | Issue: 7 | Pages: e003019

10.1136/jitc-2021-003019 | PMID 34230114 Get It

Background Human telomerase reverse transcriptase (hTERT) is frequently classified as a ‘universal’ tumor associated antigen due to its expression in a vast number of cancers. We evaluated plasmid DNA-encoded hTERT as an immunotherapy across nine cancer types. Methods A phase 1 clinical trial was conducted in adult patients with no evidence of disease following definitive surgery and standard therapy, who were at high risk of relapse. Plasmid DNA encoding one of two hTERT variants (INO-1400 or INO-1401) with or without plasmid DNA encoding interleukin 12 (IL-12) (INO-9012) was delivered intramuscularly concurrent with the application of the CELLECTRA constant-current electroporation device 4 times across 12 weeks. Safety assessments and immune monitoring against native (germline, non-mutated, non-plasmid matched) hTERT antigen were performed. The largest cohort of patients enrolled had pancreatic cancer, allowing for additional targeted assessments for this tumor type. Results Of the 93 enrolled patients who received at least one dose, 88 had at least one adverse event; the majority were grade 1 or 2, related to injection site. At 18 months, 54.8% (51/93) patients were disease-free, with median disease-free survival (DFS) not reached by end of study. For patients with pancreatic cancer, the median DFS was 9 months, with 41.4% of these patients remaining disease-free at 18 months. hTERT immunotherapy induced a de novo cellular immune response or enhanced pre-existing cellular responses to native hTERT in 96% (88/92) of patients with various cancer types. Treatment with INO-1400/INO-1401±INO-9012 drove hTERT-specific IFN-γ production, generated hTERT-specific CD4+ and CD8+ T cells expressing the activation marker CD38, and induced hTERT-specific activated CD8 +CTLs as defined by cells expressing perforin and granzymes. The addition of plasmid IL-12 adjuvant elicited higher magnitudes of cellular responses including IFN-γ production, activated CD4+ and CD8+ T cells, and activated CD8+CTLs. In a subset analysis of pancreatic cancer patients, the presence of immunotherapy-induced activated CD8+ T cells expressing PD-1, granzymes and perforin correlated with survival. Conclusions Plasmid DNA-encoded hTERT/IL-12 DNA immunotherapy was well-tolerated, immune responses were noted across all tumor types, and a specific CD8+ phenotype increased by the immunotherapy was significantly correlated with survival in patients with pancreatic cancer.
Critically Ill Patients Treated for Chimeric Antigen Receptor-Related Toxicity: A Multicenter Study*
Gutierrez, Cristina, Brown, Anne Rain T., May, Heather P., Beitinjaneh, Amer, Stephens, R. Scott, Rajendram, Prabalini, Nates, Joseph L., Pastores, Stephen M., Dharshan, Ananda, Moraes, Alice Gallo de, Hensley, Matthew K., Feng, Lei, Brudno, Jennifer N., Athale, Janhavi, Ghosh, Monalisa, Kochenderfer, James N., Arias, Alejandro S., Lin, Yi, McEvoy, Colleen, Mead, Elena, Westin, Jason, Kostelecky, Natalie, Mian, Agrima, Herr, Megan M., Lin, Yi , Beitinjaneh, Amer , Kochenderfer, James N. , Brown, Anne Rain , De Moraes, Alice Gallo, Lin, Yi , Gutierrez, Cristina, Brown, Anne Rain T., May, Heather P., Stephens, R. Scott, Rajendram, Prabalini, Nates, Joseph L., Pastores, Stephen M., Dharshan, Ananda, Moraes, Alice Gallo de, Hensley, Matthew K., Feng, Lei, Brudno, Jennifer N., Athale, Janhavi, Ghosh, Monalisa, Arias, Alejandro S., Lin, Yi, McEvoy, Colleen, Mead, Elena, Westin, Jason, Kostelecky, Natalie, Mian, Agrima, Herr, Megan M.

Mayo Clinic

Critical Care Medicine | July 5, 2021 | Volume: 50 | Issue: 1 | Pages: 81-92

10.1097/ccm.0000000000005149 | PMID 34259446 Get It

OBJECTIVES: To report the epidemiology, treatments, and outcomes of adult patients admitted to the ICU after cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome. DESIGN: Retrospective cohort study SETTING: Nine centers across the U.S. part of the chimeric antigen receptor-ICU initiative. PATIENTS: Adult patients treated with chimeric antigen receptor T-cell therapy who required ICU admission between November 2017 and May 2019. INTERVENTIONS: Demographics, toxicities, specific interventions, and outcomes were collected. RESULTS: One-hundred five patients treated with axicabtagene ciloleucel required ICU admission for cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome during the study period. At the time of ICU admission, the majority of patients had grade 3–4 toxicities (66.7%); 15.2% had grade 3–4 cytokine release syndrome and 64% grade 3–4 immune effector cell-associated neurotoxicity syndrome. During ICU stay, cytokine release syndrome was observed in 77.1% patients and immune effector cell-associated neurotoxicity syndrome in 84.8% of patients; 61.9% patients experienced both toxicities. Seventy-nine percent of patients developed greater than or equal to grade 3 toxicities during ICU stay, however, need for vasopressors (18.1%), mechanical ventilation (10.5%), and dialysis (2.9%) was uncommon. Immune Effector Cell-Associated Encephalopathy score less than 3 (69.7%), seizures (20.2%), status epilepticus (5.7%), motor deficits (12.4%), and cerebral edema (7.9%) were more prevalent. ICU mortality was 8.6%, with only three deaths related to cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome. Median overall survival time was 10.4 months (95% CI, 6.64–not available mo). Toxicity grade or organ support had no impact on overall survival; higher cumulative corticosteroid doses were associated to decreased overall and progression-free survival. CONCLUSIONS: This is the first study to describe a multicenter cohort of patients requiring ICU admission with cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy. Despite severe toxicities, organ support and in-hospital mortality were low in this patient population.
Abstract TP31: Variability of Stroke Patients Meeting Endovascular Stroke Trial Criteria in a Non-clinical Trial Setting
Fugate, Jennifer E. , Brinjikji, Waleed , Cloft, Harry J. , Kallmes, David F. , Rabinstein, Alejandro A.

Mayo Clinic

Stroke | July 3, 2021 | Volume: 47 | Issue: suppl_1 | Pages: No page available

10.1161/str.47.suppl_1.tp31 Get It

Introduction: Five randomized trials proving the efficacy and safety of mechanical embolectomy for ischemic stroke patients used differing radiological methods to select patients for treatment. Hypothesis: The percentage of patients evaluated in a non-clinical trial setting that would meet radiological criteria to be included in the five trials will differ substantially. Methods: Retrospective study of consecutive ischemic stroke patients who were considered for endovascular stroke therapy based on confirmed intracranial large vessel occlusion (M1, M2, or carotid terminus) at an academic medical center from April 2010 - November 2014. All patients underwent CT perfusion and CT angiogram. Results: The table shows baseline characteristics of 119 patients. Median age was 69 years (IQR 57-79) and median NIHSS 18 (IQR 14-21). Most patients had ASPECTS score ≥ 6 (n=105, 88.2%). The M1 segment of MCA was the most common vessel occluded (n=81, 68%). All 119 patients (100%) met radiological criteria for MR CLEAN while 105 (88.2%) met criteria for SWIFT-PRIME, 96 (80.7%) for REVASCAT, 80/116 (69.0%) for EXTEND IA, and 74 (62.2%) for ESCAPE. IV TPA was given to 58 patients (48.7%) and acute endovascular stroke therapy attempted in 66 (55.5%). Any intracranial hemorrhage was more common in the patients treated with endovascular therapy than in those who were not (36% vs. 17%, p=0.025). The frequency of symptomatic ICH did not significantly differ between these two groups (6.1% vs 3.8%, p=0.691). Conclusions: The percentage of patients with acute stroke and large vessel occlusion that would qualify for endovascular stroke trials based on radiological criteria varies considerably (62%-100%) in a non-clinical trial cohort from an academic comprehensive stroke center. Additional individual patient characteristics influence treatment decisions in non-clinical trial settings.
Abstract TMP42: Distinguishing Clinical and Radiologic Features of Non-Traumatic Convexal Subarachnoid Hemorrhage
Graff‐Radford, Jonathan , Fugate, Jennifer E. , Klaas, James P. , Brown, Robert D. , Flemming, Kelly D. , Rabinstein, Alejandro A.

Mayo Clinic

Stroke | July 3, 2021 | Volume: 47 | Issue: suppl_1 | Pages: No page available

10.1161/str.47.suppl_1.tmp42 Get It

Introduction: Small case series have suggested that cerebral amyloid angiopathy (CAA) and reversible cerebral vasoconstriction syndrome (RCVS) are the most common causes of non-traumatic convexal SAH (cSAH). Our objective was to describe the spectrum of clinical and imaging features in a large series of non-traumatic cSAH patients. Methods: A retrospective observational study of consecutive patients with non-traumatic cSAH was performed. The Mayo Clinic Medical Records Linkage system was used to identify all patients evaluated at Mayo Clinic in Rochester with potential non-traumatic cSAH between January 1, 1996 and October 1, 2014. Clinical and radiologic data were abstracted from the comprehensive medical record. Results: We identified 88 patients [median age, 64 years (range: 25-85)] with non-traumatic cSAH. The most common causes were reversible cerebral vasoconstriction syndrome (26, 29.5%), cerebral amyloid angiopathy (23, 26.1%), indeterminate (14, 15.9%), and endocarditis (9, 10.2%). Other causes include posterior reversible encephalopathy syndrome, cerebral vein thrombosis, vasculitis, carotid occlusive disease, thrombosed developmental venous anomaly, and hyperperfusion syndrome after carotid revascularization. CAA patients commonly presented at an older age than RCVS patients (75 years vs 51 years, p<0.0001). The most common clinical presentation for CAA was sensorimotor dysfunction while thunderclap headache was the most common presentation of RCVS. Thirteen patients (14.7%) had recurrent cSAH and twelve patients (13.6%) had a subsequent intracerebral hemorrhage over a median follow up of 16 months. The risk was high among CAA patients, with subsequent lobar ICH occurring in 43.5% of cases, superficial siderosis in 95%, and recurrent cSAH in 39.1%, compared to 3.8%, 28.5% and 7.7% respectively in RCVS. Conclusions: Our study demonstrates the clinical diversity of cSAH. Older age, sensorimotor dysfunctions suggest CAA as the underlying cause. Younger age and thunderclap headache predict RCVS. Various other causes also need to be considered in the differential diagnosis. CAA patients have high rates of subsequent lobar ICH, development of superficial siderosis, and recurrent cSAH.
Abstract WMP115: The Metabolic Syndrome Components and Cognitive Decline: The Atherosclerosis Risk in Communities (ARIC) Study
Sharrett, Richey, Coker, Laura H., Dearborn, Jennifer L. , Knopman, David S. , Schneider, Andrea L.C. , Jack, Clifford R. , Alonso, Álvaro , Selvin, Elizabeth , Mosley, Thomas H. , Gottesman, Rebecca F.

Mayo Clinic

Stroke | July 3, 2021 | Volume: 44 | Issue: suppl_1 | Pages: No page available

10.1161/str.44.suppl_1.awmp115 Get It

Background: Midlife obesity is associated with dementia in later life, but how the metabolic syndrome (MetS) relates to cognitive change is less understood. We hypothesized that MetS would be more predictive of 6-year cognitive decline than its individual components in a large biethnic cohort (the ARIC study) and that combinations of risk factors would further increase likelihood of change. Methods: The MetS was defined in 1987-89 on 10,687 participants with two cognitive assessments at two time points. In subjects aged 44 to 66, obesity measures included body mass index (BMI) and waist-to-hip ratio (WTHR). The main outcome measure was change in 1990-92 to 96-99 of three cognitive tests: Delayed Word Recall (DWR), Digit Symbol Substitution Test (DSST), and Word Fluency Test (WFT). Linear and logistic regressions were all adjusted for age, combined race-center, sex, education, smoking, drinking, coronary artery disease and prior stroke. Change was measured as the difference divided by the number of years between visits. Results: At baseline, the prevalence of MetS was 22% (mean age 54 years, 27% black, 55% female, and 28% BMI>30 kg/m2). Subjects with MetS performed in the lowest test quintile (adjusted ORs: DWR 1.3 95% CI 1.1-1.4) in 1996-99, and much of this effect size was explained by an elevated WTHR (DWR OR 1.3 CI 1.1-1.5) and diabetes (DWR OR 1.4 CI 1.2-1.7). MetS was not associated with annual cognitive change, and diabetes was the only significant component associated with change (adjusted beta: DWR 0.03 p=.01, DSST 0.2 p<.001, WFT 0.09 p=.01). Conclusion: MetS at ages 44 to 66 was associated with worse cognitive function at follow-up, but not with annual cognitive decline over several years. Elevated WTHR and diabetes explained most of the association of MetS with cognitive function measures, and diabetes with cognitive decline. Until we have a definition of the MetS more based on pathophysiology, the components of the MetS should be the focus of analysis in future studies.